Sirtex to be Featured on The Economic Report for Liver Cancer Treatment Awareness

Strategic Insights -

A recent cancer treatment solution will be showcased on an episode of The Economic Report, highlighting Sirtex's innovative SIR-Spheres microspheres therapy for liver cancer patients. The segment focuses on the challenges in treating metastatic liver tumors and explores the benefits of SIR-Spheres microspheres in providing patients with a minimally-invasive treatment option. The episode will air locally on CNN throughout the afternoon on Friday, March 6, featuring expert commentary and personal stories from cancer survivors who were treated with microsphere therapy.

Key Takeaways:

  • Sirtex's SIR-Spheres microspheres are the only FDA-approved microsphere therapy for colorectal liver metastases, providing a minimally-invasive treatment option for patients.
  • The segment will highlight the challenges of treating metastatic liver tumors and the role of SIR-Spheres microspheres in providing patients with a viable treatment option.
  • Microsphere therapy is available to patients in Boston, with a full list of treating sites available on the Sirtex website (www.sirtex.com).
  • The treatment has been shown to improve patient survival rates and quality of life, with a response rate higher than other forms of treatment.
  • Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have a better prognosis, with increased life expectancy and improved quality of life.
  • SIR-Spheres microspheres have been approved for use in Australia, the United States of America (FDA approval), and the European Union (CE Mark), with approximately 7,500 patients treated worldwide.
  • The treatment has been found to shrink liver tumors more than chemotherapy alone, providing a new hope for patients with liver cancer.

Statistics:

  • At least 60% of the nearly 150,000 Americans diagnosed with colorectal cancer every year will see their cancer spread to the liver.
  • SIR-Spheres microspheres selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
  • The treatment has been used in approximately 7,500 patients worldwide, with ongoing clinical trials to confirm its effectiveness.
  • Clinical trials have shown that liver cancer patients treated with SIR-Spheres microspheres have a response rate of higher than other forms of treatment, resulting in increased life expectancy and improved quality of life.

Sources:

  • Sirtex Medical Inc.: "SIR-Spheres microspheres"
  • The Economic Report: "Medical Innovations for the 21st Century"
  • Cancer Weekly: "Sirtex, Medical Inc: SIR-Spheres microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy."